Ark Therapeutics PLC's listing on the London Stock Exchange (LSE) in March 2004 was the first biotech IPO in Europe in three years. The company's offering raised £55 million ($102 million) giving Ark a market capitalization on listing of £168 million.
When the company announced its intention to list, all eyes turned to its performance, with some observers declaring this would...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?